Investing

Erasca : ERAS

ERAS

Stock Data

$10.03

$0.62 (5.82%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Erasca Inc is a trailblazing biopharmaceutical company dedicated to defeating cancer. With a sharp focus on RAS/MAPK pathway-driven cancers, Erasca is advancing a promising pipeline of potential therapies. Its leading candidates, ERAS-007 and ERAS-601, target various cancers including lung, colorectal, and acute myeloid leukemia, as well as advanced solid tumors. Additionally, Erasca is developing ERAS-801 for recurrent brain cancer. Founded in 2018, this San Diego-based company is on a mission to transform cancer treatment.

All Erasca Articles

2 Articles

Joel South | Mar 9, 2026 at 11:17 AM EDT

uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts

Wall Street is turning constructive on three clinical-stage biotechs simultaneously, each sitting at the edge of a binary catalyst. The…

Trey Thoelcke | Dec 14, 2023 at 8:50 AM EST

What Has Insiders Eyeing This Biotech Stock

A biotech stock rallying on encouraging trial results prompted insider buying and selling. A specialty retailer and others saw insider…